SCHEMBL5902530

SCHEMBL5902530

CCOC(=O)c1cc(C(C)=O)c(=O)[nH]c1C1CC1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.66
▸ POLB P06746 3/20 0.66
▸ NPC1 O15118 1/20 0.66
▸ ALDH1A1 P00352 7/20 0.55
▸ MAPT P10636 4/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ CDK5 Q00535 1/20 0.52
▸ CDK5R1 Q15078 1/20 0.52
▸ KDM4E B2RXH2 7/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ PLAT P00750 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5901624 0.86 ALDH1A1 (0.51) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL4871436 0.80 GAA (1.00) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL8832560 0.79 GAA (0.75) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL5901793 0.77 GAA (0.73) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL9476375 0.77 GAA (0.88) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL5901547 0.75 GAA (0.69) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL5901930 0.75 GAA (0.69) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL5901932 0.74 GAA (0.68) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL7781229 0.73 ALDH1A1 (0.55) GAAPOLBNPC1ALDH1A1MAPT
SCHEMBL9671945 0.71 ALDH1A1 (1.00) GAAPOLBNPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060241151-A1 Pyrid-2-one derivatives and methods of use AMGEN, INC. (US) 2006-10-26 — — US disclosed
EP-1575947-A1 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES Amgen Inc. (US) 2005-09-21 — — EP disclosed
US-20040147561-A1 Pyrid-2-one derivatives and methods of use SYNGENTA CROP PROTECTION AG (CH) 2004-07-29 — — US disclosed
WO-2004060890-A1 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES AMGEN INC. (US) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147561-A1 Pyrid-2-one derivatives and methods of use PLPBP, PNPO, PDXK GAA 977/4885POLB 912/4885NPC1 1629/4885
US-20060241151-A1 Pyrid-2-one derivatives and methods of use PLPBP, PNPO, PDXK GAA 987/4885POLB 896/4885NPC1 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback